Search

In the past 30 years, major strides have been made in translational medicine — the bridge that shepherds research findings from the lab to clinical practice. Researchers, physicians, and other specialists at Memorial Sloan Kettering Cancer Center (MSK) have played a major role in these successes, as they work together with the common goal of using their discoveries to create new treatments for people with cancer.

… Friday, August 12, 2022 In the past 30 years, major strides have been made in translational medicine — the bridge that shepherds research findings from the lab to clinical practice. Researchers, physicians, and other specialists at Memorial Sloan Kettering Cancer Center (MSK) have played a major role

The list honors health care leaders who envision a better future for all New Yorkers.

… Wednesday, December 1, 2021 Craig B. Thompson, MD , President and CEO of Memorial Sloan Kettering Cancer Center (MSK), has been named to the first AMNY Metro and PoliticsNY ’s Power Players in Health Care list. The list salutes top public officials, policymakers, hospital and health maintenance organization

Sometimes a BRCA mutation is just along for the ride, rather than driving a tumor’s development.

… Wednesday, July 10, 2019 VIDEO | 00:54 Watch: Not All BRCA Mutations Cause Patients' Cancer, Study Finds Computational biologist Barry Taylor discusses findings of a new study about BRCA genes. Video Details Summary Scientists at Memorial Sloan Kettering have discovered that BRCA1 and BRCA2 mutations

A team of doctors and researchers at MSK have identified a new, rare type of small cell lung cancer that primarily affects younger people who have never smoked. Learn how one 19-year-old patient sparked a detective story.

… Wednesday, September 11, 2024 A team of doctors and researchers at Memorial Sloan Kettering Cancer Center (MSK) have identified a new, rare type of small cell lung cancer that primarily affects younger people who have never smoked. Their findings, which include a detailed analysis of the clinical and

Un equipo de médicos e investigadores de MSK ha identificado un nuevo y raro tipo de cáncer pulmonar de células pequeñas que afecta principalmente a personas jóvenes que nunca han fumado. Descubra cómo un paciente de 19 años inspiró una historia de investigación.

… Wednesday, September 11, 2024 Un equipo de médicos e investigadores del Memorial Sloan Kettering Cancer Center (MSK) ha identificado un nuevo y raro tipo de cáncer pulmonar de células pequeñas que afecta principalmente a personas jóvenes que nunca han fumado. Sus hallazgos, que incluyen un análisis detallado

A new imaging approach being investigated by Memorial Sloan Kettering researchers could provide better information about a tumor’s molecular activity, allowing for a more accurate diagnosis.

… Wednesday, September 25, 2013 Summary A new imaging approach being investigated by Memorial Sloan Kettering researchers could provide better information about a tumor’s molecular activity, allowing for a more accurate diagnosis. A new imaging approach being investigated by Memorial Sloan Kettering researchers

Learn why medical oncologist Ghassan Abou-Alfa counsels his patients with liver cancer to stop drinking.

… Wednesday, December 23, 2015 Summary Many people with primary liver cancer wonder if it’s safe to keep drinking alcohol. The fact is that alcohol is toxic to liver cells and consuming alcohol can accelerate liver damage with sometimes fatal consequences in people with this cancer. In addition, treatment

Inheriting a mutation in the CDH1 gene can raise risk of a rare stomach cancer called hereditary diffuse gastric cancer.

… Thursday, July 22, 2021 Stomach (gastric) cancer is the third leading cause of cancer deaths in the world today. About 10% of these cancers are due to a genetic mutation inherited from a parent. One specific mutation, called CDH1 , puts a person at very high risk for a rare but lethal form of stomach

Memorial Sloan Kettering researchers have found a naturally occurring compound that can destroy cancer cells in mice by targeting MYC, a cancer-causing gene that has remained elusive until now.

… Monday, July 28, 2014 Summary Memorial Sloan Kettering researchers have found a naturally occurring compound that can destroy cancer cells in mice by targeting MYC , a cancer-causing gene that has remained elusive until now. Many of the most effective cancer therapies available today have been developed

Researchers learn how prostate cancer cells change their type to survive treatment.

… Friday, September 2, 2022 Cancer cells are adept at developing ways to evade treatments. For example, prostate cancer prostate cancer becomes resistant to hormone therapy hormone therapy by changing a protein called the androgen receptor (AR), which plays a key role in determining cellular identity.